ECE2018 Poster Presentations: Adrenal and Neuroendocrine Tumours Endocrine tumours and neoplasia (34 abstracts)
Evaluation of neurofibromatosis type 1 and gastroenteropancreatic neuroendocrine tumors.
Juan Carlos Percovich , José Atencia , Rogelio García , Marcel Sambo , Montserrat Blanco , Amanda Rotger , Dolores López , Yoko Olmedilla , María Picallo , Marián Vélez , Javier Agreda , Noemí Brox & Susana Monereo
Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Introduction: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with an incidence of 1 in 2600 to 3000 individuals. Patients with this disorder are characterized by multiple neurofibromas, caf-au-lait macules, axillary freckling, optic gliomas, iris hamartomas, and skeletal abnormalities. Overall risk of developing neoplasms is approximately 2 to 4-fold higher in patients with NF1, with a risk of malignancy estimated between 5 and 15%. Endocrinopathies are sometimes associated with this condition. Patients with NF1 usually assessed at Endocrinology consultation are those who suffer from gastroenteropancreatic neuroendocrine tumours (NET) (~1.0%) and/or pheochromocytomas/paragangliomas (~0.1-5.0%). Gastroenteropancreatic involvement in NF1 includes gastrointestinal stromal tumors (GIST), carcinoids, somatostatinomas, gastrinomas, insulinomas and nonfunctioning pancreatic tumors.
Methods: We identified 11 patients with NF1 who are still ongoing follow-ups at the Endocrinology Service of our Centre. Of those, two were found to be affected by NETs. We describe the demographic characteristics, the age of diagnosis, the type of tumor and its current status.
Results: Case 1. A 58-year-old woman that underwent an enucleation of a pancreatic somastotatinoma at the age of 15. She has non-specific lesions in the liver, but none with evidence of metastases and on the other hand has high chromogranin a (CgA) levels, therefore she is being treated with a somatostatin analogue.
Case 2. A 70-year-old man proceded to a pancreatoduodenectomy of a dudodenal somastotinoma at the age of 67. The tumor size was 25 mm and the average Ki67<5%. There is currently no evidence of metastases and CgA levels are normal.
Conclusions: Although association of gastroenteropancreatic NETs in the context of patients with NF1 is uncommon, these patients’ treating physicians should be aware of such possibility. Surgical removal of the NET is the first-line therapy and is potentially curable if there is no significant delay in the diagnosis.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more